Korean researchers have screened 48 FDA-approved drugs against SARS-CoV-2, and found that 2, which are already FDA-approved for other illnesses, seem promising.
The FDA approval for other uses would greatly reduce the time needed to gain FDA approval of use in COVID-19. The research is published in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.
The investigators tested the drugs in Vero cells, a cell line developed from kidney cells of the African Green Monkey, which are commonly used to grow viruses for vaccine production.
An anti-helminthic drug called niclosamide demonstrated “very potent” antiviral activity against SARS-CoV-2, according to coauthors Sangeun Jeon, Meehyun Ko, and their collaborators, of the Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, Korea. “Not surprisingly, its broad-spectrum antiviral effect has been well documented in the literature, including antiviral properties against SARS- and MERS-CoV,” they write.
A downside of niclosamide is low absorption, which undercuts the drug’s power by reducing the dose that reaches the target tissue. However, “Further development or drug formulation could enable effective delivery of this drug to the target tissue,” according to the report.
Despite substantially lower antiviral potency, ciclesonide, an inhaled corticosteroid used to treat asthma and allergic rhinitis, also showed promise against SARS-CoV-2. Intriguingly, the investigators note that a study published earlier this year ( by Matsuyama et al.) a treatment report of 3 patients infected by SARS-CoV-2, demonstrated antiviral activity and revealed the drug’s molecular target to be a viral protein called Nsp15.
“With its proven anti-inflammatory activity, ciclesonide may represent as a potent drug which can manifest [the] dual roles [of antiviral and anti-inflammatory] for the control of SARS-CoV-2 infection,” the investigators conclude. The anti-inflammatory activity might play a critical role in dampening or preventing the cytokine storms, an immune inflammatory overreaction that can kill COVID-19 patients.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- SARS-CoV-2 detected in Ontario wildlife for the first time
Ontario has detected its first cases of SARS-CoV-2 in wildlife according to the Ministry of Natural Resources and Forestry.
- Study: Maternal SARS-CoV-2 infection may affect newborn’s immune system
SARS-CoV-2 infection during pregnancy may cause inflammatory immune responses in the fetus, even if the virus does not infect the placenta, according to a small National Institutes of Health ...
- Researchers find newer variants of SARS-CoV-2 can infect mice, unlike the original version of the virus
A team of biology researchers at Georgia State University has found that some of the newer variants of the virus that causes COVID-19 can infect the respiratory tract of wild mice, unlike the original ...
- 'Decoy' protein works against multiple SARS-CoV-2 variants
A drug treatment that acts as a decoy against SARS-CoV-2 was highly effective at preventing death and lung damage in humanized animal models of severe COVID-19 disease, according to a Nature Chemical ...
- Major Protease Of SARS-CoV-2 Acts To Suppress Innate Immunity
In October 2020, researchers discovered that the SARS-CoV-2 nonstructural protein 5 (NSP5) suppresses innate immunity. This has key implications for Covid-19 drug development that have yet to be fully ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- NBC Sports will not send broadcasters to Beijing Olympics due to COVID-19 concerns
NBC Sports is pulling back its Beijing Olympics broadcasting teams due to concerns over COVID-19, according to Christine Brennan of USA Today. NBC Sports' senior vice president of communications Greg ...
- Free COVID-19 testing site opens at DePaul’s Loop campus
U. of I.'s Shield Illinois now has 24 testing sites statewide. DePaul’s Loop campus partnership marks the nonprofit’s third testing site in Chicago.
- NBC won't send announcers to 2022 Winter Olympics in Beijing due to COVID-19
NBC's broadcasting teams for figure skating, Alpine skiing and snowboarding had been expected to be in Beijing.
- District 7 staff shortage mitigated by updated Covid-19 guidance
In a letter issued to District 7 families on Sunday, Superintendent Patrick Shelton announced that of the 125 staff members currently affected by COVID-19, 73 were eligible to return on Tuesday. The ...
- Dave Bing 'disappointed' in Kyrie Irving's COVID-19 vaccine stance
I’m very disappointed in his position,” Bing told Yahoo Sports. “I respect his position but very disappointed. Because basketball is a team game, team sport. You let your teammates down.” ...